Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lamb Weston Holdings Inc (LW) vs TransMedics Group Inc (TMDX) Price & Performance

Lamb Weston Holdings IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Lamb Weston Holdings Inc vs TransMedics Group Inc — how do they compare? Lamb Weston Holdings Inc trades at $46.42 (market cap $6.43B), while TransMedics Group Inc trades at $73.86 (market cap $2.54B). The key difference: Lamb Weston Holdings Inc is far larger — about 2.5× TransMedics Group Inc's market cap, and Lamb Weston Holdings Inc pays a 3.26% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

LWTMDX
Market Cap
$6.43B$2.54B
Sector
Consumer StaplesTechnology
52-Week High
$66.57$150.42
52-Week Low
$38.48$61.99
Enterprise Value
$10.40B$2.94B
Dividend Yield
3.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lamb Weston Holdings Inc

Lamb Weston (LW) trades at $46.59, down 0.43% today, with a bullish technical signal from moving averages and a consensus analyst price target of $49.33. The company reported revenue of $6.45B in 2025 and has beaten EPS estimates in the last three quarters. Recent news highlights its 'Focus to Win' strategy showing traction, with volume gains in North America and cost-saving initiatives supporting its turnaround.

The outlook remains cautiously optimistic, with potential upside from continued earnings beats and strategic execution, but risks include a pending class-action lawsuit, margin pressures, and high debt levels. Analyst sentiment is mixed, with 35% buy ratings, reflecting confidence in the turnaround amid operational challenges.

TransMedics Group Inc

TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.

Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lamb Weston Holdings Inc

Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.

Read more on LW

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX